Dr Tori Oliver
Senior Technical Advisor
Tori joined the Nossal Institute in 2020 as a Senior Technical Advisor in the Maternal Sexual and Reproductive Health Unit.
Prior to joining the team, Tori worked as part of a public private partnership for the development of a novel, heat stable oxytocin inhaler for the prevention of postpartum haemorrhage in low-resource settings. From 2015-2020, Tori led the market access program for the project, in which she led a large-scale formative implementation research program exploring the perceived acceptability and operational feasibility of the novel oxytocin product amongst community members, healthcare providers and policy-makers in high need settings. As part of the development of an implementation strategy, Tori co-ordinated an in-depth assessment of the readiness of health systems in Sub-Saharan Africa and South Asia to adopt a novel uterotonic in order to prioritise first launch countries for inhaled oxytocin.
Through her work on the inhaled oxytocin project, Tori has supported research programs exploring medicines quality issues in low and middle income settings. This has included a post-marketing surveillance study evaluating the quality of oxytocin in three regions of Ethiopia. Qualitative research in Myanmar, Ethiopia and India, explored stakeholder knowledge, attitudes and practices towards oxytocin stability and storage and highlighted health system-wide factors impacting oxytocin quality.
Tori holds a Bachelor of Medicinal Chemistry and completed her PhD in Pharmaceutical Science at Monash University in 2011.